# EDGAR Filing Document

**Accession Number:** 0001342916
**File Stem:** 0000000000-25-008132
**Filing Date:** 2025-8
**Character Count:** 9278
**Document Hash:** 212bc6dfb50ccbe7ab7154101270d622
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008132.hdr.sgml**: 20260630

**ACCESSION NUMBER**: 0000000000-25-008132

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250801

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HNO International, Inc.
- **CENTRAL INDEX KEY:** 0001342916
- **STANDARD INDUSTRIAL CLASSIFICATION:** METAL MINING [1000]
- **ORGANIZATION NAME:** 01 Energy & Transportation
- **EIN:** 202781289
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 024-12607

**BUSINESS ADDRESS:**
- **STREET 1:** 41558 EASTMAN DRIVE, SUITE B
- **CITY:** MURRIETA
- **STATE:** CA
- **ZIP:** 92562
- **BUSINESS PHONE:** 951-305-8872

**MAIL ADDRESS:**
- **STREET 1:** 41558 EASTMAN DRIVE, SUITE B
- **CITY:** MURRIETA
- **STATE:** CA
- **ZIP:** 92562

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Excoin Ltd.
- **DATE OF NAME CHANGE:** 20210830

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Clenergen Corp
- **DATE OF NAME CHANGE:** 20100317

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CLENERGEN Corp
- **DATE OF NAME CHANGE:** 20090324
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001262463-25-000109

## Text-Extract

```

                                                             August 1, 2025

Donald Owens
President
HNO International, Inc.
41558 Eastman Drive, Suite B
Murrieta, CA 92562

       Re: HNO International, Inc.
           Offering Statement on Form 1-A
           Filed July 21, 2025
           File No. 024-12607
Dear Donald Owens:

     We have reviewed your amended offering statement and have the following
comments.

       Please respond to this letter by amending your offering statement and
providing the
requested information. If you do not believe a comment applies to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your offering statement and the
information you
provide in response to this letter, we may have additional comments. Unless we
note
otherwise, any references to prior comments are to comments in our May 23, 2025
letter.

Amendment to Offering Statement on Form 1-A
Cover Page

1.     You state on the cover that your offering includes "Up to 333,333 Shares
of Common
       Stock Offered by the Company." Please revise to clarify that these
shares are being
       offered by the Selling Shareholder.
2.     We note your disclosure here and elsewhere that the Subject Convertible
Note, will,
       by its terms, be eligible for conversion into shares of your common
stock "at the
       election of its holder." However, Article I. of the Convertible
Promissory Note, dated
       April 7, 2025, states that the holder shall have the right "from to
time, and at any time
       during the period beginning on the date which is one hundred eighty
(180) days
       following the date of this Note" to convert all or any part of the
outstanding and
       unpaid amount of the Note. Please advise or revise.
 August 1, 2025
Page 2

3.     We note footnote 4 to your tabular disclosure states that the principal
amount of the
       Subject Convertible Note is $50,000 and that such amount was determined
by adding
       the principal amount, $50,000, and an assumed $5,000 of accrued interest
therein.
       However, your disclosure above states that the principal amount of the
Subject
       Convertible Note is $45,000. Please revise or advise.
Offering Summary, page 4

4.     Please tell us how you determined there were 90,970,491 shares issued
and
       outstanding as of the date hereof. In this regard, we note that
outstanding shares at
       April 30, 2025 were 80,150,491 per the balance sheet on page F-1 and
that 3,700,000
       shares were issued between May 1 and June 18, 2025 per Note 12 on page
F-16.
Use of Proceeds, page 12

5.     We note you disclose that your tabular disclosure reflects the estimated
proceeds you
       would derive assuming an offering price of $1.00, which represents the
midpoint of
       the offering price range. However, we note you disclose a price range of
$[0.15-
       1.00]. Please advise or revise. We note Regulation A requires that you
use the upper
       end of your price range to disclose the aggregate offering amount of
this offering.
       Refer to Rule 253(b)(2) of Regulation A.
Plan of Distribution
Procedures for Subscribing, page 15

6.     We note you disclose that in connection with determining whether to
accept or reject a
       subscription you intend to consider, among other things, your
then-current need for a
       cash investment; the state of the securities markets, in general, and
the market for
       [your] common stock, in particular.    Please confirm your understanding
that Rule
       251(d)(3)(i)(F) of Regulation A is limited to offerings that commence
within two
       calendar days after qualification and are made on a continuous basis
during the
       offering period. Relatedly, please also confirm your understanding that
in a
       continuous offering, an issuer must be ready and willing to sell the
aggregate amount
       of securities qualified at all times.
Business
Our Products, page 19

7.     We note the additional disclosure added in response to our prior comment
10. As
       indicated by Item 10(b) of Regulation S-K, management's projections of
future
       economic performance must have a reasonable basis and be presented in an
       appropriate format, including the financial items to be projected, the
period to be
       covered, and the manner of presentation to be used. Traditionally
projections have
       been given for three financial items generally considered to be of
primary importance
       to investors: revenues, net income (loss), and earnings (loss) per
share. We note that
       you have provided some revenues, some costs and some operating and gross
profits
       for your products. Please address the following:
           We note that you have two employees. Please disclose how you will
construct 10-
           40 units of each product in the next 15-20 months.
           We note that you don't provide projected revenues and costs for your
SHEP
 August 1, 2025
Page 3

           Platform product, yet provide projected gross profit. Please
disclose how you can
           calculate projected gross profit without projected revenues and
costs.
             As to the Hydrogen production locations, you detail projected
revenues of $15-25
           million but do not include a projected gross profit. Please disclose
projected gross
           profit or disclose why you cannot provide. In this regard, we note
that you expect
           expenditures of $20 million over the next 15-20 months.
             Disclose projected net income(loss) or disclose why you cannot
provide.
8.     We note that you have built a CHRS unit and it is being marketed for
sale. Please tell
       us where this unit is presented in your condensed balance sheet at April
30, 2025.
Directors, Executive Officers, Promoters and Control Persons, page 29

9.     We note your revised disclosure reflects that you have three directors.
However, we
       also note your references to your "sole director." Please revise or
advise.
Certain Relationships and Related Transactions
Advances from Related Party, page 34

10.    We note your response to our prior comment 16. Please revise to clarify
whether
       interest accrues on the advances and when the outstanding balances are
due.
Unaudited Financial Statements for the Six Months Ended April 30, 2025
Unaudited Condensed Balance Sheets at April 30, 2025 and October 31, 2024, page
F-1

11.    We note your response to comment 17 and disclosure at page 20 stating
that 10 units
       remain unsold and in inventory. Tell us where the amounts are presented
in your
       condensed balance sheet as of April 30, 2025.
General

12.    We note you disclose in Item 4 of Part I that you are offering
50,000,000 securities in
       this offering. Please revise to include the total number of shares being
qualified under
       your offering statement, including the 333,333 Selling Shareholder
Offered Shares.
13.    We note your revised disclosure includes references to Offered Shares,
Company
       Offered Shares and Selling Shareholder Offered Shares. Please consider
whether the
       context of each use of such term is sufficiently clear or whether
further revision would
       be appropriate.
 August 1, 2025
Page 4

        Please contact Brian McAllister at 202-551-3341 or Kimberly Calder at
202-551-3701
if you have questions regarding comments on the financial statements and
related
matters. Please contact Anuja Majmudar at 202-551-3844 or Karina Dorin at
202-551-3763
with any other questions.

                                                         Sincerely,

                                                         Division of
Corporation Finance
                                                         Office of Energy &
Transportation
cc:   Eric Newlan

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._